Search Results - "Post, M.C"

Long-term real world clinical outcomes of macitentan therapy in chronic thromboembolic pulmonary hypertension by van Thor, M.C.J., ten Klooster, L., Snijder, R.J., Mager, J.J., Post, M.C.

“…Macitentan treatment for chronic thromboembolic pulmonary hypertension (CTEPH) in the routine clinical setting is increasing. However, ‘real world’ macitentan…”
Get full text

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension by van Thor, M.C.J., ten Klooster, L., Snijder, R.J., Post, M.C., Mager, J.J.

“…To improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat. The aim…”
Get full text

Echocardiographic pulmonary hypertension probability is associated with clinical outcomes after transcatheter aortic valve implantation by Nijenhuis, V.J, Huitema, M.P, Vorselaars, V.M.M, Swaans, M.J, de Kroon, T, van der Heyden, J.A.S, Rensing, B.J.W.M, Heijmen, R, ten Berg, J.M, Post, M.C

“…Abstract Aims Pulmonary hypertension (PH) is associated with mortality after transcatheter aortic valve implantation (TAVI). However, diagnosis based on…”
Get full text

Does combination therapy work in chronic thromboembolic pulmonary hypertension? by van Thor, M.C.J., Snijder, R.J., Kelder, J.C., Mager, J.J., Post, M.C.

“…•Long-term overall survival of CTEPH patients receiving PH-specific medial therapy is very reasonable.•Despite worse baseline characteristics at baseline,…”
Get full text

Uncertainties in insurances for adults with congenital heart disease by Sluman, M.A, Apers, S, Bouma, B.J, van Melle, J.P, Peels, C.H, Post, M.C, Waskowsky, W.M, Moons, P, Mulder, B.J.M

Get full text

PREVALENCE OF PULMONARY ARTERIAL HYPERTENSION IN ADULT CONGENITAL HEART DISEASE by van Riel, Annelieke CMJ, Schuuring, Mark, van Hessen, Irene D, Zwinderman, Aeilko, Cozijnsen, Luc, Reichert, Stan C.L.A, Hoorntje, Jan, Wagenaar, Lodewijk, Post, M.C, Van Dijk, Arie, Hoendermis, Elke, Mulder, Barbara, Bouma, Berto

Get full text

Quality of life in pulmonary arterial hypertension by Post, M.C., Mager, J.J.

“…The majority of the studies on QoL in PAH patients used different standard generic questionnaires or tools specific for heart or lung diseases, not reflecting…”
Get full text

Echocardiographic findings associated with mortality or transplant in patients with pulmonary arterial hypertension: A systematic review and meta-analysis by Baggen, V.J.M., Driessen, M.M.P., Post, M.C., van Dijk, A.P., Roos-Hesselink, J.W., van den Bosch, A.E., Takkenberg, J.J.M., Sieswerda, G.T

“…Background Identification of patients at risk of deterioration is essential to guide clinical management in pulmonary arterial hypertension (PAH). This study…”
Get full text

Graded Transthoracic Contrast Echocardiography After Pulmonary Arteriovenous Malformation Embolization by Hessels, J., Klompmaker, S., van den Heuvel, D.A.F., Boerman, S., Mager, J.J., Post, M.C.

Get full text

(1017) - High Incidence of In-Hospital Venous Thromboembolism Early After Lung Transplantation Despite Thromboprophylaxis by Ruigrok, D., Admiraal, J., Boersma, L., Schonwetter, R., Post, M.C., Luijk, B.

Get full text

Evolution of Pulmonary Arteriovenous Malformations by Hessels, J., Kroon, S., Vorselaars, V.V.M., Boerman, S., Mager, J.J., Post, M.C.

“…Pulmonary arteriovenous malformations (PAVMs) are direct connections between the pulmonary artery and the pulmonary vein, mostly associated with hereditary…”
Get full text

Value of echocardiography using knowledge-based reconstruction in determining right ventricular volumes in pulmonary sarcoidosis: comparison with cardiac magnetic resonance imaging by Mathijssen, H, Huitema, M.P, Bakker, A.L.M, Akdim, F, Van Es, H.W, Grutters, J.C, Post, M.C

“…Abstract Background Right ventricular (RV) dysfunction in sarcoidosis is associated with adverse outcomes. Assessment of RV function by conventional…”
Get full text

Mortality in a well-defined group of predominantly Caucasian pulmonary sarcoidosis patients by Huitema, M.P, Mathijssen, H, Bakker, A.L.M, Mager, J.J, Grutters, J.C, Post, M.C

“…Abstract Background Sarcoidosis is an inflammatory systemic disease. Mortality has often been described in patients with more advanced disease, especially in…”
Get full text

Aetiology of sarcoidosis-associated pulmonary hypertension by Mathijssen, H, Huitema, M.P, Bakker, A.L.M, Smits, F, Snijder, R.J, Mager, H.J, Grutters, J.C, Post, M.C

“…Abstract Background Pulmonary hypertension (PH) is a known complication of pulmonary sarcoidosis and its aetiology is unclear. The severity of PH may not…”
Get full text

31Exercise induced intracardiac right-to-left shunt with elevation of the pulmonary artery pressure in a patient with pulmonary sarcoidosis by Huitema, M.P., Bakker, A.L.M., Drent, M., Grutters, J.C., Post, M.C.

Get full text

CMR markers for early right ventricular dysfunction in precapillary pulmonary hypertension by Vos, J, Leiner, T, Van Dijk, A.P.J, Meijboom, F.J, Sieswerda, G.T, Snijder, R.J, Post, M.C, Nijveldt, R, Driessen, M.M.P

“…Abstract Introduction Precapillary pulmonary hypertension (pPH) causes right ventricular (RV) pressure overload inducing RV remodeling, often resulting in…”
Get full text

Long-term monitoring of arrhythmias in cardiac sarcoidosis by Bakker, A, Mathijssen, H, Balt, J, Van Dijk, V.F, Veltkamp, M, Swaans, M, Akdim, F, Grutters, J.C, Post, M.C

“…Abstract Introduction Screening for cardiac sarcoidosis (CS) is recommended since it can manifest with ventricular arrhythmias (VA), atrioventricular…”
Get full text

Effectiveness and safety of infliximab in cardiac Sarcoidosis by Bakker, A.L.M., Mathijssen, H., Azzahhafi, J., Swaans, M.J., Veltkamp, M., Keijsers, R.G.M., Akdim, F., Post, M.C., Grutters, J.C.

“…Immunosuppressive therapy in active cardiac sarcoidosis (CS) might prevent potential life-threatening complications. Infliximab (IFX) is a tumor necrosis…”
Get full text

Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study by Yang, H., Bouma, B.J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Greutmann, M., Schwerzmann, M., Egbe, A., Scognamiglio, G., Budts, W., Veldtman, G., Opotowsky, A.R., Broberg, C.S., Gumbiene, L., Meijboom, F.J., Rutz, T., Post, M.C., Moe, T., Lipczyńska, M., Tsai, S.F., Chakrabarti, S., Tobler, D., Davidson, W., Morissens, M., van Dijk, A., Buber, J., Bouchardy, J., Skoglund, K., Christersson, C., Kronvall, T., Konings, T.C., Alonso-Gonzalez, R., Mizuno, A., Webb, G., Laukyte, M., Sieswerda, G.T.J., Shafer, K., Aboulhosn, J., Mulder, B.J.M.

“…Current guidelines consider vitamin K antagonists (VKA) the oral anticoagulant agents of choice in adults with atrial arrhythmias (AA) and moderate or complex…”
Get full text

P3376One-year follow up after transcatheter treatment of heart failure with preserved ejection fraction using an inter-atrial implant: a single centre case series by Snijder, R.J.R., Swaans, M.J., Van Der Heyden, J.A.S., Kelder, J.C., Post, M.C.

Get full text